-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BLU-451 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BLU-451 in Non-Small Cell Lung Cancer Drug Details: BLU-451 (LNG-451) under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BLU-451 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BLU-451 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BLU-451 in Non-Small Cell Lung Cancer Drug Details:BLU-451 (LNG-451) under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BLU-945 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BLU-945 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BLU-945 in Non-Small Cell Lung CancerDrug Details:BLU-4810 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BLU-222 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BLU-222 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BLU-222...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LBL-007 in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LBL-007 in Laryngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LBL-007 in Laryngeal Cancer Drug Details: LBL-007 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Pancreatic Cancer Drug Details: Pralsetinib (Gavreto) is an anticancer agent. It is formulated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Medullary Thyroid Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Medullary Thyroid Cancer Drug Details: Pralsetinib (Gavreto) is an anticancer agent. It is...